<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178085</url>
  </required_header>
  <id_info>
    <org_study_id>PI2014_843_0007</org_study_id>
    <secondary_id>2014-A00847-40</secondary_id>
    <nct_id>NCT02178085</nct_id>
  </id_info>
  <brief_title>Ocular Blood Flow Assessment in Glaucoma</brief_title>
  <acronym>OBAMAg</acronym>
  <official_title>Ocular Blood-flow Assessment by Magnetic Resonance Angiography in Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Glaucoma is a common disease, potentially blinding, characterized by progressive&#xD;
      damage to the optic nerve. If the intraocular pressure is the most known risk factor,&#xD;
      however, there are cases of glaucoma scalable despite well-controlled intraocular pressure,&#xD;
      ocular hypertension without glaucoma or glaucoma without ocular hypertension (normal tension&#xD;
      glaucoma).&#xD;
&#xD;
      Purpose :Involvement of vascular factors in the development of glaucoma and scalability has&#xD;
      been proved, associated with a possible loss of vascular autoregulation. The objective of&#xD;
      this study is to quantify MRI flow of blood flows referred ophthalmic patients with glaucoma&#xD;
      untreated comparison with control subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eye vascularization, supplied by ophthalmic artery and superior ophthalmic vein is not easily&#xD;
      accessible to routine explorations to date. Similarly the potential oscillations of the&#xD;
      cerebrospinal fluid (CSF) around the optic nerve have not been described. Developments in&#xD;
      magnetic resonance imaging (MRI) provide new insights into the quantitative study of blood&#xD;
      and CSF flows through phase contrast MRI also called &quot;flow MRI&quot;. Our hypothesis is that the&#xD;
      ability of MRI to measure intracranial flow is applicable to the vasculature of the eye.&#xD;
&#xD;
      The MRI protocol will be applied to control adult subjects previously examined by an&#xD;
      ophthalmologist. Structures to be imaged will be identified on a morphological sequence. Each&#xD;
      MRI phase contrast slice (flow MRI) will be positioned perpendicularly to the flow direction.&#xD;
      The flow MRI data will be analysed by a dedicated image processing tool which performs the&#xD;
      vessels segmentation. For each curve of the vessel flow evolution during the cardiac cycle is&#xD;
      reconstructed.&#xD;
&#xD;
      Glaucomatous patients will undergo a six-month follow-up to determine if they respond to&#xD;
      their therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial blood flow</measure>
    <time_frame>Day 1</time_frame>
    <description>Measure of the mean arterial blood flow during the cardiac cycle in the ophthalmic artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular flow curves</measure>
    <time_frame>Day 1</time_frame>
    <description>Temporal and amplitude parameters of vascular flow curves (arteries and veins)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) dynamic</measure>
    <time_frame>Day 1</time_frame>
    <description>Temporal and amplitude parameters of cerebrospinal fluid (CSF) curves measured in the optic nerve sheath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>Day 180</time_frame>
    <description>Determination of treatment response&#xD;
Measurement of ocular tone (21 mmHg threshold under which the patient may be responder to treatment value)&#xD;
Extent of the visual field (if stable patient responder)&#xD;
Measure optic disc (if stable patient responder)&#xD;
The three conditions must be true to declare a patient responder to treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Flow imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glaucoma patients and healthy subjects who will undergo ocular flow imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flow imaging</intervention_name>
    <description>Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.</description>
    <arm_group_label>Flow imaging</arm_group_label>
    <other_name>Flow MRI</other_name>
    <other_name>Cine phase-constrast magnetic resonance imaging</other_name>
    <other_name>Cerebral blood flow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants&#xD;
&#xD;
          -  Diagnosis of primary open angle glaucoma or normal-tension glaucoma&#xD;
&#xD;
          -  Never received any anti glaucoma therapy&#xD;
&#xD;
          -  Patients included in the group &quot; normal pressure glaucoma &quot; are patients where the&#xD;
             diagnosis of optic neuropathy have been worn by the ophthalmologist with measured&#xD;
             intraocular pressure &lt;21 mmHg.&#xD;
&#xD;
          -  Healthy controls will be examined by an ophthalmologist before inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone with a classic contraindication to MRI&#xD;
&#xD;
          -  Cardiovascular comorbidities or neurovascular : uncontrolled systemic hypertension ,&#xD;
             Diabetes, heart failure , carotid stenosis , ischemic stroke or transient ischemic&#xD;
             attack.&#xD;
&#xD;
          -  Already treated glaucoma&#xD;
&#xD;
          -  Prescription by the ophthalmologist another treatment than prostaglandin analogue&#xD;
             treatment.&#xD;
&#xD;
          -  Other clinical forms of glaucoma : angle closure glaucoma, neovascular glaucoma,&#xD;
             exfoliative glaucoma, secondary glaucomas, pigment dispersion glaucoma, traumatic&#xD;
             glaucoma, congenital glaucoma&#xD;
&#xD;
          -  Presence of other ocular pathology (simple refractive error allowing 10/10 of best&#xD;
             corrected visual acuity and mild and moderate cataracts will not be considered as a&#xD;
             criterion for non- inclusion).&#xD;
&#xD;
          -  History of intraocular or orbital surgery of less than 6 months .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Balédent, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Balédent, PhD</last_name>
    <phone>+33 3 22 66 86 73</phone>
    <email>olivier.baledent@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Balédent, PhD</last_name>
      <phone>+33 3 22 66 86 73</phone>
      <email>olivier.baledent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Solange Milazzo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Baledent, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Promelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'ophtalmologie Victor Pauchet</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Thomas, MD</last_name>
      <phone>+33 3 22 91 75 44</phone>
    </contact>
    <investigator>
      <last_name>Fabrice Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>phase-contrast MRI</keyword>
  <keyword>blood flow</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

